Oakwood Medical Investors
VC Fund
St Louis, United States
Oakwood Medical Investors is a venture capital fund invests in development stage medical device, biopharmaceutical and healthcare service.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Oakwood Medical Investors invests in
Health CareMedicalTherapeuticsBiotechnologyMedical Device
Stages Oakwood Medical Investors invests in
Series CSeries BSeries D
Countries Oakwood Medical Investors invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Daniel A. Burkhardt
|
|||
|
James L. Nouss
|
|||
|
Jason A. Darrah
|
|||
Raul E. Perez
|
|||
1 more contact available
Investment Focus
Industry
- Health Care 6 (55%)
- Medical 4 (36%)
- Therapeutics 3 (27%)
- Biotechnology 3 (27%)
- Medical Device 3 (27%)
Stage
- Series C 8 (73%)
- Series B 1 (9%)
- Series D 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Daniel A. Burkhardt
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
James L. Nouss
Director
|
Director | Total investments: 0 | Find email | |
|
Jason A. Darrah
Director of Research
|
Director of Research | Total investments: 0 | Find email | |
|
Raul E. Perez
President and a Managing Director
|
President and a Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EMKinetics
|
EMKinetics, Inc. provides a therapy to prevent urinary incontinence by using electric pulses. The company is based in San Francisco, California. | $8M / Series C / Oct 18, 2011 | |
|
EMKinetics
|
EMKinetics, Inc. provides a therapy to prevent urinary incontinence by using electric pulses. The company is based in San Francisco, California. | $2.8M / Series B / Mar 12, 2010 | |
Mitralign
|
Mitralign is a venture backed privately held company located in a suburb of Boston, MA. The company is developing an innovative catheter based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system emulates surgical annuloplasty as it delivers a series of surgical implants directly into the mitralannulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.Mitralign is funded by top tier venture capitalists and has two major cardiovascular device companies as investors. | $24M / Series C / Dec 31, 2007 | |
EKOS Corporation
|
EKOS Corporation pioneered the development and the clinical application of ultrasound accelerated thrombolysis, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System toprovide faster, safer and more complete dissolution of thrombus. | $26M / Series C / Mar 21, 2006 | |
Quick Study Radiology
|
Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communicationsystems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri. | $1.2M / Series C / Jul 15, 2005 | |
Spherics
|
As of August 4, 2008, Spherics, Inc. went out of business. Spherics, Inc., a pharmaceutical company, engages in developing and manufacturing oral pharmaceutical products for central nervous system conditions, gastrointestinal disorders, and cancer. It develops oral systems based on the application of bioadhesive polymers to oral dosage forms. Thecompany also provides products for neurological disorders, such as Alzheimer's, Parkinson's, and multiple sclerosis, as well as for stroke, epilepsy, chronic pain, and migraine. The company was founded in 1997 and is headquartered in Mansfield, Massachusetts. | $26.4M / Series C / May 13, 2005 | |
|
Spherics
|
Spherics develops proprietary bioadhesive encapsulation technologies to improve the oral absorption of small molecule drugs. | $26.4M / Series C / May 12, 2005 | |
|
Quick Study Radiology
|
Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communicationsystems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri. | $902K / Series C / Oct 14, 2004 | |
Insulet
|
Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes primarily in the United States. The company offers OmniPod Insulin Management System (OmniPod System), an insulin infusion system that provides a pain-free automated cannulainsertion. The OmniPod System consists of OmniPod disposable insulin infusion device and handheld wireless personal diabetes manager; and provides people with a diabetes management solution that offers lifestyle and other benefits. The company sells the OmniPod System directly to patients through referrals from healthcare professionals and through patient leads. Insulet Corporation was founded in 2000 and is headquartered in Bedford, Massachusetts. | Series D / Mar 02, 2004 | |
TransMolecular
|
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technologyplatforms to enrich its product discovery and development pipeline.Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms.The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama.TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively. | $33.2M / Series C / Mar 01, 2004 | |
| See all 11 investments → | |||
Co-Investors
Easton Capital
3 deals together
Advent International
2 deals together
A.G. Edwards Capital Partners
2 deals together
Fletcher Spaght, Inc.
2 deals together
Legacy Life Sciences
2 deals together
MedVenture Associates
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Oakwood Medical Investors invest in?
Oakwood Medical Investors invests primarily in Health Care, Medical and Therapeutics startups, most often at Series C and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Oakwood Medical Investors?
Public channels for Oakwood Medical Investors include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oakwood Medical Investors?
The team at Oakwood Medical Investors includes Daniel A. Burkhardt (Managing Director), James L. Nouss (Director) and Jason A. Darrah (Director of Research). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
